The findings of a single-arm cohort study involving 42 patients with refractory and/or relapsed B-cell lymphoblastic leukaemia (B-ALL) indicate that low-dose (1 × 105/kg) chimeric antigen receptor (CAR) T cells are safe and effective in this setting. 90% of patients entered complete remission,

中文翻译：

---

血液系统癌症：低剂量CAR T细胞安全有效

一项涉及42例难治性和/或复发性B细胞淋巴母细胞白血病（B-ALL）患者的单臂队列研究的结果表明，低剂量（1×105 / kg）嵌合抗原受体（CAR）T细胞是安全的在这种情况下有效 90％的患者进入完全缓解状态，